SOST and postmenopausal osteoporosis: Clinically, humanized therapeutic sclerostin antibody (romosozumab) which bound to both loop2 and loop3 on sclerostin demonstrated bone anabolic potential for postmenopausal osteoporosis, whereas imposed severe cardiac ischemic events (BRIDGE and ARCH) 5-8, 13.